SK9372000A3 - Substituted beta-alanines - Google Patents

Substituted beta-alanines Download PDF

Info

Publication number: SK9372000A3
Authority: SK; Slovakia
Prior art keywords: compound; group; alkyl; acetyl; amino
Prior art date: 1997-12-23

Application number

SK937-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Peter Charles Astles

Neil Victor Harris

Andrew David Morley

Original Assignee

Rhone Poulenc Rorer Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-23

Filing date

1998-12-23

Publication date

2002-03-05

1997-12-23 Priority claimed from GBGB9727532.5A external-priority patent/GB9727532D0/en

1998-12-23 Application filed by Rhone Poulenc Rorer Ltd filed Critical Rhone Poulenc Rorer Ltd

2002-03-05 Publication of SK9372000A3 publication Critical patent/SK9372000A3/sk

Links

UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical class NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims abstract description 564
125000000217 alkyl group Chemical group 0.000 claims abstract description 94
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 60
150000003839 salts Chemical class 0.000 claims abstract description 58
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 53
239000000651 prodrug Substances 0.000 claims abstract description 35
229940002612 prodrug Drugs 0.000 claims abstract description 35
239000001257 hydrogen Substances 0.000 claims abstract description 21
239000012453 solvate Substances 0.000 claims abstract description 21
125000003545 alkoxy group Chemical group 0.000 claims abstract description 20
229910052736 halogen Inorganic materials 0.000 claims abstract description 16
150000002367 halogens Chemical class 0.000 claims abstract description 16
150000002431 hydrogen Chemical class 0.000 claims abstract 7
-1 cyclic amine Chemical class 0.000 claims description 352
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 264
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 163
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 129
235000019260 propionic acid Nutrition 0.000 claims description 127
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 110
125000004432 carbon atom Chemical group C* 0.000 claims description 73
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 65
239000011347 resin Substances 0.000 claims description 64
229920005989 resin Polymers 0.000 claims description 64
125000003118 aryl group Chemical group 0.000 claims description 48
239000000203 mixture Substances 0.000 claims description 44
125000001072 heteroaryl group Chemical group 0.000 claims description 39
238000000034 method Methods 0.000 claims description 39
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 35
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
125000000753 cycloalkyl group Chemical group 0.000 claims description 25
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 24
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 23
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 23
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 21
230000002378 acidificating effect Effects 0.000 claims description 18
238000011282 treatment Methods 0.000 claims description 18
125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 14
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
125000003710 aryl alkyl group Chemical group 0.000 claims description 14
125000002947 alkylene group Chemical group 0.000 claims description 13
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
229910052760 oxygen Inorganic materials 0.000 claims description 13
229910005965 SO 2 Inorganic materials 0.000 claims description 12
125000003342 alkenyl group Chemical group 0.000 claims description 12
239000003112 inhibitor Substances 0.000 claims description 12
230000021164 cell adhesion Effects 0.000 claims description 11
150000004677 hydrates Chemical class 0.000 claims description 11
229910052717 sulfur Inorganic materials 0.000 claims description 11
125000000524 functional group Chemical group 0.000 claims description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 8
125000000304 alkynyl group Chemical group 0.000 claims description 7
125000004043 oxo group Chemical group O=* 0.000 claims description 7
125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 6
230000001404 mediated effect Effects 0.000 claims description 6
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 6
229940126062 Compound A Drugs 0.000 claims description 5
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 5
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
230000001668 ameliorated effect Effects 0.000 claims description 5
125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 5
125000004122 cyclic group Chemical group 0.000 claims description 5
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
238000002560 therapeutic procedure Methods 0.000 claims description 5
125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 4
125000002252 acyl group Chemical group 0.000 claims description 4
125000004450 alkenylene group Chemical group 0.000 claims description 4
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
125000000732 arylene group Chemical group 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
125000002993 cycloalkylene group Chemical group 0.000 claims description 4
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
PRZMGAZLBSVGFD-UHFFFAOYSA-N 3-[(3,4-dimethoxyphenyl)methyl-[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]acetyl]amino]propanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CN(CCC(O)=O)C(=O)CN(C)C(=O)CC(C=C1OC)=CC=C1NC(=O)NC1=CC=CC=C1C PRZMGAZLBSVGFD-UHFFFAOYSA-N 0.000 claims description 3
125000002619 bicyclic group Chemical group 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
125000005518 carboxamido group Chemical group 0.000 claims description 3
125000006588 heterocycloalkylene group Chemical group 0.000 claims description 3
125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000005842 heteroatom Chemical group 0.000 claims description 2
208000027866 inflammatory disease Diseases 0.000 claims description 2
125000004434 sulfur atom Chemical group 0.000 claims description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 11
238000004519 manufacturing process Methods 0.000 claims 2
125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
125000001475 halogen functional group Chemical group 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
108010067306 Fibronectins Proteins 0.000 abstract description 14
102000016359 Fibronectins Human genes 0.000 abstract description 14
108010008212 Integrin alpha4beta1 Proteins 0.000 abstract description 10
230000003993 interaction Effects 0.000 abstract description 8
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 1
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 235
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 96
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
230000000052 comparative effect Effects 0.000 description 51
239000002253 acid Substances 0.000 description 47
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
239000000243 solution Substances 0.000 description 44
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 41
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 32
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
238000001819 mass spectrum Methods 0.000 description 28
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
239000007787 solid Substances 0.000 description 27
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
210000004027 cell Anatomy 0.000 description 22
238000004128 high performance liquid chromatography Methods 0.000 description 22
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 20
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 18
239000002585 base Substances 0.000 description 17
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
108010044426 integrins Proteins 0.000 description 16
102000006495 integrins Human genes 0.000 description 16
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
238000000921 elemental analysis Methods 0.000 description 15
239000011734 sodium Substances 0.000 description 15
125000003373 pyrazinyl group Chemical group 0.000 description 14
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 11
125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
238000010828 elution Methods 0.000 description 9
150000002148 esters Chemical class 0.000 description 9
BEYOHIUUBRQWQF-UHFFFAOYSA-N ethyl 3-[(3,4-dimethoxyphenyl)methylamino]propanoate Chemical compound CCOC(=O)CCNCC1=CC=C(OC)C(OC)=C1 BEYOHIUUBRQWQF-UHFFFAOYSA-N 0.000 description 9
239000006260 foam Substances 0.000 description 9
239000012458 free base Substances 0.000 description 9
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 8
239000012442 inert solvent Substances 0.000 description 8
239000003446 ligand Substances 0.000 description 8
229910052943 magnesium sulfate Inorganic materials 0.000 description 8
235000019341 magnesium sulphate Nutrition 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
125000001931 aliphatic group Chemical group 0.000 description 7
150000001412 amines Chemical class 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
125000002883 imidazolyl group Chemical group 0.000 description 7
238000003018 immunoassay Methods 0.000 description 7
125000004076 pyridyl group Chemical group 0.000 description 7
238000003756 stirring Methods 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
125000004442 acylamino group Chemical group 0.000 description 6
239000000427 antigen Substances 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
206010003246 arthritis Diseases 0.000 description 6
230000027455 binding Effects 0.000 description 6
239000012267 brine Substances 0.000 description 6
125000004494 ethyl ester group Chemical group 0.000 description 6
230000007062 hydrolysis Effects 0.000 description 6
238000006460 hydrolysis reaction Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 6
239000003960 organic solvent Substances 0.000 description 6
238000005897 peptide coupling reaction Methods 0.000 description 6
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
125000002102 aryl alkyloxo group Chemical group 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
239000000284 extract Substances 0.000 description 5
125000002541 furyl group Chemical group 0.000 description 5
125000001041 indolyl group Chemical group 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
230000014759 maintenance of location Effects 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
230000008569 process Effects 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
125000003435 aroyl group Chemical group 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
125000005843 halogen group Chemical group 0.000 description 4
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
125000002950 monocyclic group Chemical group 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000000126 substance Substances 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
HJORCZCMNWLHMB-UHFFFAOYSA-N 1-(3-aminopropyl)pyrrolidin-2-one Chemical compound NCCCN1CCCC1=O HJORCZCMNWLHMB-UHFFFAOYSA-N 0.000 description 3
LQAWZBVFPYYFGB-UHFFFAOYSA-N 2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1NC(=O)NC1=CC=CC=C1C LQAWZBVFPYYFGB-UHFFFAOYSA-N 0.000 description 3
125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 3
125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
208000009525 Myocarditis Diseases 0.000 description 3
108010058846 Ovalbumin Proteins 0.000 description 3
241001494479 Pecora Species 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
239000003875 Wang resin Substances 0.000 description 3
NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
125000004644 alkyl sulfinyl group Chemical group 0.000 description 3
125000004414 alkyl thio group Chemical group 0.000 description 3
125000004419 alkynylene group Chemical group 0.000 description 3
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
125000004659 aryl alkyl thio group Chemical group 0.000 description 3
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
125000005110 aryl thio group Chemical group 0.000 description 3
125000004104 aryloxy group Chemical group 0.000 description 3
238000003556 assay Methods 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
239000012230 colorless oil Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000009510 drug design Methods 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
210000003979 eosinophil Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
125000005114 heteroarylalkoxy group Chemical group 0.000 description 3
125000005553 heteroaryloxy group Chemical group 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
239000003791 organic solvent mixture Substances 0.000 description 3
229940092253 ovalbumin Drugs 0.000 description 3
230000004044 response Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000002904 solvent Substances 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 2
125000004512 1,2,3-thiadiazol-4-yl group Chemical group S1N=NC(=C1)* 0.000 description 2
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 2
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 2
WJXSKIOLUFTCLL-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)methylamino]methyl]butanoic acid Chemical compound CCC(CNCc1ccc(OC)c(OC)c1)C(O)=O WJXSKIOLUFTCLL-UHFFFAOYSA-N 0.000 description 2
125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
TXPKUUXHNFRBPS-UHFFFAOYSA-N 3-(2-carboxyethylamino)propanoic acid Chemical compound OC(=O)CCNCCC(O)=O TXPKUUXHNFRBPS-UHFFFAOYSA-N 0.000 description 2
IPANWGXQYMVWLM-UHFFFAOYSA-N 3-[[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]acetyl]-(pyridin-4-ylmethyl)amino]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)NCC(=O)N(CCC(O)=O)CC1=CC=NC=C1 IPANWGXQYMVWLM-UHFFFAOYSA-N 0.000 description 2
WBVVRXOGPNPHQQ-UHFFFAOYSA-N 3-[furan-2-ylmethyl-[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]acetyl]amino]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)N(C)CC(=O)N(CCC(O)=O)CC1=CC=CO1 WBVVRXOGPNPHQQ-UHFFFAOYSA-N 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 2
125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 2
VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
101710178046 Chorismate synthase 1 Proteins 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
101710152695 Cysteine synthase 1 Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229910021380 Manganese Chloride Inorganic materials 0.000 description 2
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
208000018262 Peripheral vascular disease Diseases 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
102100032831 Protein ITPRID2 Human genes 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
108010021119 Trichosanthin Proteins 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
108010031318 Vitronectin Proteins 0.000 description 2
102100035140 Vitronectin Human genes 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
210000005058 airway cell Anatomy 0.000 description 2
208000037883 airway inflammation Diseases 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
239000003513 alkali Substances 0.000 description 2
125000005036 alkoxyphenyl group Chemical group 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
125000005239 aroylamino group Chemical group 0.000 description 2
125000005135 aryl sulfinyl group Chemical group 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
150000001558 benzoic acid derivatives Chemical class 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
CWJSHJJYOPWUGX-UHFFFAOYSA-N chlorpropham Chemical compound CC(C)OC(=O)NC1=CC=CC(Cl)=C1 CWJSHJJYOPWUGX-UHFFFAOYSA-N 0.000 description 2
150000001860 citric acid derivatives Chemical class 0.000 description 2
206010009887 colitis Diseases 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000002327 eosinophilic effect Effects 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
XRYQSHFICQLFKT-UHFFFAOYSA-N ethyl 3-(3-imidazol-1-ylpropylamino)propanoate Chemical compound CCOC(=O)CCNCCCN1C=CN=C1 XRYQSHFICQLFKT-UHFFFAOYSA-N 0.000 description 2
QYWYQRHYEHCZIG-UHFFFAOYSA-N ethyl 3-(3-phenylpropylamino)propanoate Chemical compound CCOC(=O)CCNCCCC1=CC=CC=C1 QYWYQRHYEHCZIG-UHFFFAOYSA-N 0.000 description 2
GUWJCSNPDDLJPJ-UHFFFAOYSA-N ethyl 3-[(3-ethoxy-4-methoxyphenyl)methylamino]propanoate Chemical compound CCOC(=O)CCNCC1=CC=C(OC)C(OCC)=C1 GUWJCSNPDDLJPJ-UHFFFAOYSA-N 0.000 description 2
OPVUJRMELCIOHY-UHFFFAOYSA-N ethyl 3-[(3-methoxy-4-phenylmethoxyphenyl)methylamino]propanoate Chemical compound COC1=CC(CNCCC(=O)OCC)=CC=C1OCC1=CC=CC=C1 OPVUJRMELCIOHY-UHFFFAOYSA-N 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
239000000499 gel Substances 0.000 description 2
FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 2
CJFGBCWGOQRURQ-UHFFFAOYSA-N ginsenoside Mc Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CJFGBCWGOQRURQ-UHFFFAOYSA-N 0.000 description 2
125000005059 halophenyl group Chemical group 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
125000005241 heteroarylamino group Chemical group 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
125000005956 isoquinolyl group Chemical group 0.000 description 2
150000003903 lactic acid esters Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
150000002688 maleic acid derivatives Chemical class 0.000 description 2
150000002690 malonic acid derivatives Chemical class 0.000 description 2
239000011565 manganese chloride Substances 0.000 description 2
235000002867 manganese chloride Nutrition 0.000 description 2
229940099607 manganese chloride Drugs 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
HTVPOIPEQRQGSC-UHFFFAOYSA-N methyl 2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetate Chemical compound COC1=CC(CC(=O)OC)=CC=C1NC(=O)NC1=CC=CC=C1C HTVPOIPEQRQGSC-UHFFFAOYSA-N 0.000 description 2
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
LPWAKYISHIZIPO-UHFFFAOYSA-N morpholin-4-ylmethyl benzoate Chemical class C=1C=CC=CC=1C(=O)OCN1CCOCC1 LPWAKYISHIZIPO-UHFFFAOYSA-N 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
230000023578 negative regulation of cell adhesion Effects 0.000 description 2
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
150000003901 oxalic acid esters Chemical class 0.000 description 2
150000004965 peroxy acids Chemical class 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
229940117803 phenethylamine Drugs 0.000 description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
125000005493 quinolyl group Chemical group 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
150000003902 salicylic acid esters Chemical class 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
150000003900 succinic acid esters Chemical class 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
150000003899 tartaric acid esters Chemical class 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
238000005406 washing Methods 0.000 description 2
LVMPWFJVYMXSNY-UHFFFAOYSA-N (2,3-dimethoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1OC LVMPWFJVYMXSNY-UHFFFAOYSA-N 0.000 description 1
PXJACNDVRNAFHD-UHFFFAOYSA-N (2-methoxyphenyl)methanamine Chemical compound COC1=CC=CC=C1CN PXJACNDVRNAFHD-UHFFFAOYSA-N 0.000 description 1
FFEARJCKVFRZRR-ZBSMTAPBSA-N (2s)-2-amino-4-methylsulfanyl-2-tritiobutanoic acid Chemical compound OC(=O)[C@](N)([3H])CCSC FFEARJCKVFRZRR-ZBSMTAPBSA-N 0.000 description 1
DIVNUTGTTIRPQA-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1OC DIVNUTGTTIRPQA-UHFFFAOYSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
ZILSBZLQGRBMOR-UHFFFAOYSA-N 1,3-benzodioxol-5-ylmethanamine Chemical compound NCC1=CC=C2OCOC2=C1 ZILSBZLQGRBMOR-UHFFFAOYSA-N 0.000 description 1
125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
HHEKNWQXFVOUNJ-UHFFFAOYSA-N 1-(2-aminoethyl)pyrrolidin-2-one Chemical compound NCCN1CCCC1=O HHEKNWQXFVOUNJ-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
CWKXDPPQCVWXAG-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-6-carbaldehyde Chemical compound O1CCOC2=CC(C=O)=CC=C21 CWKXDPPQCVWXAG-UHFFFAOYSA-N 0.000 description 1
125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
GDXCHMYGFIQDPZ-UHFFFAOYSA-N 2-(aminomethyl)-3-(9h-fluoren-9-ylmethoxy)-3-oxopropanoic acid Chemical compound C1=CC=C2C(COC(=O)C(C(O)=O)CN)C3=CC=CC=C3C2=C1 GDXCHMYGFIQDPZ-UHFFFAOYSA-N 0.000 description 1
WMWDKFOADFUFLN-UHFFFAOYSA-N 2-(naphthalen-1-ylmethylamino)propanoic acid Chemical compound C1=CC=C2C(CNC(C)C(O)=O)=CC=CC2=C1 WMWDKFOADFUFLN-UHFFFAOYSA-N 0.000 description 1
HDWMEUDJXNEIDV-UHFFFAOYSA-N 2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]propanoic acid Chemical compound COC1=CC(C(C)C(O)=O)=CC=C1NC(=O)NC1=CC=CC=C1C HDWMEUDJXNEIDV-UHFFFAOYSA-N 0.000 description 1
RUSLWOBOKXLMRG-UHFFFAOYSA-N 2-[4-(phenylcarbamoylamino)phenyl]acetic acid Chemical group C1=CC(CC(=O)O)=CC=C1NC(=O)NC1=CC=CC=C1 RUSLWOBOKXLMRG-UHFFFAOYSA-N 0.000 description 1
QQZPNLJBEVYHLN-UHFFFAOYSA-N 2-[4-(phenylcarbamoylamino)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1NC(=O)NC1=CC=CC=C1 QQZPNLJBEVYHLN-UHFFFAOYSA-N 0.000 description 1
XFISKNOLGDBFOH-UHFFFAOYSA-N 2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]acetic acid Chemical compound COC1=CC(CC(=O)NCC(O)=O)=CC=C1NC(=O)NC1=CC=CC=C1C XFISKNOLGDBFOH-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
CFBYEGUGFPZCNF-UHFFFAOYSA-N 2-nitroanisole Chemical compound COC1=CC=CC=C1[N+]([O-])=O CFBYEGUGFPZCNF-UHFFFAOYSA-N 0.000 description 1
XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 1
VAYMIYBJLRRIFR-UHFFFAOYSA-N 2-tolyl isocyanate Chemical compound CC1=CC=CC=C1N=C=O VAYMIYBJLRRIFR-UHFFFAOYSA-N 0.000 description 1
VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
SSTRYEXQYQGGAS-UHFFFAOYSA-N 3,4-diethoxybenzaldehyde Chemical compound CCOC1=CC=C(C=O)C=C1OCC SSTRYEXQYQGGAS-UHFFFAOYSA-N 0.000 description 1
YYAYTNPNFKPFNG-UHFFFAOYSA-N 3-(2-methylpiperidin-1-yl)propan-1-amine Chemical compound CC1CCCCN1CCCN YYAYTNPNFKPFNG-UHFFFAOYSA-N 0.000 description 1
OSINWSZNRNYXSY-UHFFFAOYSA-N 3-[(2-chlorophenyl)methyl-[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]acetyl]amino]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)N(C)CC(=O)N(CCC(O)=O)CC1=CC=CC=C1Cl OSINWSZNRNYXSY-UHFFFAOYSA-N 0.000 description 1
WZFRNNCNGXELDE-UHFFFAOYSA-N 3-[(3,4-dimethoxyphenyl)methyl-[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]acetyl]amino]propanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CN(CCC(O)=O)C(=O)CNC(=O)CC(C=C1OC)=CC=C1NC(=O)NC1=CC=CC=C1C WZFRNNCNGXELDE-UHFFFAOYSA-N 0.000 description 1
QVZCXKFEFBZSFG-UHFFFAOYSA-N 3-[(3,4-dimethoxyphenyl)methylazaniumyl]propanoate Chemical compound COC1=CC=C(CNCCC(O)=O)C=C1OC QVZCXKFEFBZSFG-UHFFFAOYSA-N 0.000 description 1
NGGMOISHMNIHQO-UHFFFAOYSA-N 3-[(3,5-dimethoxyphenyl)methyl-[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]acetyl]amino]propanoic acid Chemical compound COC1=CC(OC)=CC(CN(CCC(O)=O)C(=O)CNC(=O)CC=2C=C(OC)C(NC(=O)NC=3C(=CC=CC=3)C)=CC=2)=C1 NGGMOISHMNIHQO-UHFFFAOYSA-N 0.000 description 1
KTFHHZQIEFBAAF-UHFFFAOYSA-N 3-[3-imidazol-1-ylpropyl-[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]acetyl]amino]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)NCC(=O)N(CCC(O)=O)CCCN1C=CN=C1 KTFHHZQIEFBAAF-UHFFFAOYSA-N 0.000 description 1
CSIGEAMPWPZZBM-UHFFFAOYSA-N 3-[[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]acetyl]-(pyridin-2-ylmethyl)amino]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)N(C)CC(=O)N(CCC(O)=O)CC1=CC=CC=N1 CSIGEAMPWPZZBM-UHFFFAOYSA-N 0.000 description 1
AXAOICQYYZRRRH-UHFFFAOYSA-N 3-[[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]acetyl]-[(3-methoxy-4-phenylmethoxyphenyl)methyl]amino]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)NCC(=O)N(CCC(O)=O)CC(C=C1OC)=CC=C1OCC1=CC=CC=C1 AXAOICQYYZRRRH-UHFFFAOYSA-N 0.000 description 1
GQRHODVFQMWKCC-UHFFFAOYSA-N 3-[[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]acetyl]-[(3-nitrophenyl)methyl]amino]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)NCC(=O)N(CCC(O)=O)CC1=CC=CC([N+]([O-])=O)=C1 GQRHODVFQMWKCC-UHFFFAOYSA-N 0.000 description 1
NWXPSMKNXQGKMU-UHFFFAOYSA-N 3-[butyl-[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]acetyl]amino]propanoic acid Chemical compound COC1=CC(CC(=O)NCC(=O)N(CCC(O)=O)CCCC)=CC=C1NC(=O)NC1=CC=CC=C1C NWXPSMKNXQGKMU-UHFFFAOYSA-N 0.000 description 1
VAMZHXWLGRQSJS-UHFFFAOYSA-N 3-ethoxy-4-methoxybenzaldehyde Chemical compound CCOC1=CC(C=O)=CC=C1OC VAMZHXWLGRQSJS-UHFFFAOYSA-N 0.000 description 1
JSHLOPGSDZTEGQ-UHFFFAOYSA-N 3-methoxy-4-phenylmethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC=C1OCC1=CC=CC=C1 JSHLOPGSDZTEGQ-UHFFFAOYSA-N 0.000 description 1
125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 1
RSMPLTSIIKUEOM-UHFFFAOYSA-N 4-(1-carboxyethylamino)butanoic acid Chemical compound OC(=O)C(C)NCCCC(O)=O RSMPLTSIIKUEOM-UHFFFAOYSA-N 0.000 description 1
ACUIFAAXWDLLTR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)butanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCC(=O)O)C3=CC=CC=C3C2=C1 ACUIFAAXWDLLTR-UHFFFAOYSA-N 0.000 description 1
GOEYIMWLBICGRE-UHFFFAOYSA-N 4-[2-carboxyethyl-[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]acetyl]amino]butanoic acid Chemical compound COC1=CC(CC(=O)N(C)CC(=O)N(CCCC(O)=O)CCC(O)=O)=CC=C1NC(=O)NC1=CC=CC=C1C GOEYIMWLBICGRE-UHFFFAOYSA-N 0.000 description 1
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 description 1
125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000244188 Ascaris suum Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 1
NJSPYODRKUYBLX-UHFFFAOYSA-N CC(C(=O)O)NCCN1CCCC1=O Chemical compound CC(C(=O)O)NCCN1CCCC1=O NJSPYODRKUYBLX-UHFFFAOYSA-N 0.000 description 1
LEEXOPDDQBOPDI-UHFFFAOYSA-N CC1=CC=CC=C1NC(=O)NC2=C(C=C(C=C2)CC(=O)N(C)CC(=O)N(CCC(=O)O)CC3=CC=CS3)OC Chemical compound CC1=CC=CC=C1NC(=O)NC2=C(C=C(C=C2)CC(=O)N(C)CC(=O)N(CCC(=O)O)CC3=CC=CS3)OC LEEXOPDDQBOPDI-UHFFFAOYSA-N 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010078015 Complement C3b Proteins 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
241001340534 Eido Species 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical group CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000590503 Melanitis Species 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
241001024304 Mino Species 0.000 description 1
UVPSSGJTBLNVRE-UHFFFAOYSA-N Moniliformin Natural products O=C1C(OC)=CC(=O)C=2C1=C1C(=O)C(OC)=CC(=O)C1=CC=2 UVPSSGJTBLNVRE-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010042618 Surgical procedure repeated Diseases 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
206010048873 Traumatic arthritis Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000008369 airway response Effects 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000006242 amine protecting group Chemical group 0.000 description 1
VNEMVKOXLBIWTB-UHFFFAOYSA-N aminomethyl benzoate Chemical class NCOC(=O)C1=CC=CC=C1 VNEMVKOXLBIWTB-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000002152 aqueous-organic solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
WPYMKLBDIGXBTP-VQEHIDDOSA-N benzoic acid Chemical compound OC(=O)C1=CC=C[13CH]=C1 WPYMKLBDIGXBTP-VQEHIDDOSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000008619 cell matrix interaction Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
125000004803 chlorobenzyl group Chemical group 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000004956 cyclohexylene group Chemical group 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000004979 cyclopentylene group Chemical group 0.000 description 1
125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
NIDZUMSLERGAON-UHFFFAOYSA-N ethyl 2-(methylamino)acetate;hydron;chloride Chemical compound Cl.CCOC(=O)CNC NIDZUMSLERGAON-UHFFFAOYSA-N 0.000 description 1
PUPFHBJUWGJRCQ-UHFFFAOYSA-N ethyl 2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propylamino]propanoate Chemical compound CCOC(=O)C(C)NCCCNC(=O)OC(C)(C)C PUPFHBJUWGJRCQ-UHFFFAOYSA-N 0.000 description 1
QLSIFDZSOFDKNJ-UHFFFAOYSA-N ethyl 3-(2,3-dihydro-1,4-benzodioxin-6-ylmethylamino)propanoate Chemical compound O1CCOC2=CC(CNCCC(=O)OCC)=CC=C21 QLSIFDZSOFDKNJ-UHFFFAOYSA-N 0.000 description 1
GCBARIJZTQDJEQ-UHFFFAOYSA-N ethyl 3-[(2,3-dimethoxyphenyl)methylamino]propanoate Chemical compound CCOC(=O)CCNCC1=CC=CC(OC)=C1OC GCBARIJZTQDJEQ-UHFFFAOYSA-N 0.000 description 1
ASTKVDQVEYPSJB-UHFFFAOYSA-N ethyl 3-[(3,4-diethoxyphenyl)methylamino]propanoate Chemical compound CCOC(=O)CCNCC1=CC=C(OCC)C(OCC)=C1 ASTKVDQVEYPSJB-UHFFFAOYSA-N 0.000 description 1
GHIUCJYEFIEMKH-UHFFFAOYSA-N ethyl 3-[(3,4-dimethoxyphenyl)methyl-[2-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]acetyl]amino]propanoate Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)N(C)CC(=O)N(CCC(=O)OCC)CC1=CC=C(OC)C(OC)=C1 GHIUCJYEFIEMKH-UHFFFAOYSA-N 0.000 description 1
HIUIFWSGRJQOMN-UHFFFAOYSA-N ethyl 3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propylamino]propanoate Chemical compound CCOC(=O)CCNCCCNC(=O)OC(C)(C)C HIUIFWSGRJQOMN-UHFFFAOYSA-N 0.000 description 1
RJCGNNHKSNIUAT-UHFFFAOYSA-N ethyl 3-aminopropanoate;hydron;chloride Chemical compound Cl.CCOC(=O)CCN RJCGNNHKSNIUAT-UHFFFAOYSA-N 0.000 description 1
TXEPQFCHHDFYMO-UHFFFAOYSA-N ethyl 3-anilinopropanoate Chemical compound CCOC(=O)CCNC1=CC=CC=C1 TXEPQFCHHDFYMO-UHFFFAOYSA-N 0.000 description 1
MAFQLJCYFMKEJJ-UHFFFAOYSA-N ethyl 4-aminobutanoate Chemical compound CCOC(=O)CCCN MAFQLJCYFMKEJJ-UHFFFAOYSA-N 0.000 description 1
WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000010433 feldspar Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000005446 heptyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000005835 indanylene group Chemical group 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
150000002611 lead compounds Chemical class 0.000 description 1
108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
230000004807 localization Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000002609 medium Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000001466 metabolic labeling Methods 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
HKMLRUAPIDAGIE-UHFFFAOYSA-N methyl 2,2-dichloroacetate Chemical compound COC(=O)C(Cl)Cl HKMLRUAPIDAGIE-UHFFFAOYSA-N 0.000 description 1
LUQOXCWPUDHYQB-UHFFFAOYSA-N methyl 2-[4-(aminomethoxy)phenyl]acetate Chemical compound C(OC1=CC=C(CC(=O)OC)C=C1)N LUQOXCWPUDHYQB-UHFFFAOYSA-N 0.000 description 1
JXVFQHNGMWCJEK-UHFFFAOYSA-N methyl 2-chloro-2-(3-methoxy-4-nitrophenyl)acetate Chemical compound COC(=O)C(Cl)C1=CC=C([N+]([O-])=O)C(OC)=C1 JXVFQHNGMWCJEK-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
KGPQKNJSZNXOPV-UHFFFAOYSA-N moniliformin Chemical compound OC1=CC(=O)C1=O KGPQKNJSZNXOPV-UHFFFAOYSA-N 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
DAKZISABEDGGSV-UHFFFAOYSA-N n-(2-aminoethyl)acetamide Chemical compound CC(=O)NCCN DAKZISABEDGGSV-UHFFFAOYSA-N 0.000 description 1
125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
125000004957 naphthylene group Chemical group 0.000 description 1
125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
150000002829 nitrogen Chemical group 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
NLXXVSKHVGDQAT-UHFFFAOYSA-N o-(oxan-2-yl)hydroxylamine Chemical compound NOC1CCCCO1 NLXXVSKHVGDQAT-UHFFFAOYSA-N 0.000 description 1
SSUCKKNRCOFUPT-UHFFFAOYSA-N o-[tert-butyl(dimethyl)silyl]hydroxylamine Chemical compound CC(C)(C)[Si](C)(C)ON SSUCKKNRCOFUPT-UHFFFAOYSA-N 0.000 description 1
AEKHNNJSMVVESS-UHFFFAOYSA-N o-trimethylsilylhydroxylamine Chemical compound C[Si](C)(C)ON AEKHNNJSMVVESS-UHFFFAOYSA-N 0.000 description 1
125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical group 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
150000003151 propanoic acid esters Chemical class 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 1
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
125000005554 pyridyloxy group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
125000005650 substituted phenylene group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
238000010998 test method Methods 0.000 description 1
OYFUIMQYZOLBMZ-UHFFFAOYSA-J tetrachloromanganese Chemical compound Cl[Mn](Cl)(Cl)Cl OYFUIMQYZOLBMZ-UHFFFAOYSA-J 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
KBMBVTRWEAAZEY-UHFFFAOYSA-N trisulfane Chemical class SSS KBMBVTRWEAAZEY-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
229910021511 zinc hydroxide Inorganic materials 0.000 description 1
229940007718 zinc hydroxide Drugs 0.000 description 1
GSQBIOQCECCMOQ-UHFFFAOYSA-N β-alanine ethyl ester Chemical compound CCOC(=O)CCN GSQBIOQCECCMOQ-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Oncology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Indole Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Pyrrole Compounds (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

SK937-2000A 1997-12-23 1998-12-23 Substituted beta-alanines SK9372000A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9727532.5A GB9727532D0 (en)	1997-12-23	1997-12-23	Chemical compounds
US9260298P	1998-07-13	1998-07-13
PCT/GB1998/003859 WO1999033789A1 (fr)	1997-12-23	1998-12-23	β-ALANINES SUBSTITUEES

Publications (1)

Publication Number	Publication Date
SK9372000A3 true SK9372000A3 (en)	2002-03-05

Family

ID=26312873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK937-2000A SK9372000A3 (en)	1997-12-23	1998-12-23	Substituted beta-alanines

Country Status (18)

Country	Link
EP (1)	EP1042279B1 (fr)
JP (1)	JP4555469B2 (fr)
KR (1)	KR20010033520A (fr)
CN (1)	CN1163477C (fr)
AT (1)	ATE289991T1 (fr)
AU (1)	AU747907B2 (fr)
BR (1)	BR9814376A (fr)
CA (1)	CA2316235A1 (fr)
CZ (1)	CZ20002342A3 (fr)
DE (1)	DE69829215T2 (fr)
ES (1)	ES2235383T3 (fr)
HU (1)	HUP0101701A3 (fr)
IL (1)	IL136584A (fr)
NO (1)	NO20003273D0 (fr)
NZ (1)	NZ505363A (fr)
SK (1)	SK9372000A3 (fr)
TR (1)	TR200001947T2 (fr)
WO (1)	WO1999033789A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ID26665A (id) *	1998-01-23	2001-01-25	Novartis Ag	Antagonis vla-4
SK14192000A3 (sk)	1998-12-23	2001-07-10	Aventis Pharma Limited	Dihydro-benzo(1,4)oxazíny a tetrahydrochinoxalíny, ich použitie a farmaceutický prostriedok obsahujúci tieto zlúčeniny
KR100649819B1 (ko) *	1999-02-18	2007-02-28	에프. 호프만-라 로슈 아게	티오아미드 유도체
JP2003519697A (ja)	1999-12-28	2003-06-24	ファイザー・プロダクツ・インク	炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のｖｌａ−４依存性細胞結合阻害薬
DE10019755A1 (de) *	2000-04-20	2001-11-08	Bayer Ag	Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
FR2812633A1 (fr) *	2000-08-04	2002-02-08	Aventis Cropscience Sa	Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
GB2367816A (en)	2000-10-09	2002-04-17	Bayer Ag	Urea- and thiourea-containing derivatives of beta-amino acids
GB2369357A (en) *	2000-10-09	2002-05-29	Bayer Ag	Aliphatic, cyclic amino carboxylic acids as integrin antagonists
EP1330432A2 (fr)	2000-11-04	2003-07-30	Aventis Pharma Limited	Acides alcanoiqies substitues
AU2002219555B2 (en)	2000-12-28	2006-11-30	Daiichi Pharmaceutical Co., Ltd.	VLA-4 Inhibitors
GB2377933A (en)	2001-07-06	2003-01-29	Bayer Ag	Succinic acid derivatives useful as integrin antagonists
TWI340134B (en)	2003-07-24	2011-04-11	Daiichi Seiyaku Co	Cyclohexanecarboxylic acids
JP2008539246A (ja) *	2005-04-28	2008-11-13	フェリングベスローテンフェンノートシャップ	Ｉｂｄ治療のための新規化合物の使用
WO2007069635A1 (fr)	2005-12-13	2007-06-21	Daiichi Sankyo Company, Limited	Médicament inhibiteur de vla-4
CA2714335A1 (fr)	2007-02-20	2008-08-28	Merrimack Pharmaceuticals, Inc.	Methodes de traitement de la sclerose en plaques par administration d'une alpha-foetoproteine combinee a un antagoniste de l'integrine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6306840B1 (en) *	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
AU702487B2 (en) *	1995-08-30	1999-02-25	G.D. Searle & Co.	Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
CA2250464A1 (fr) *	1996-03-29	1997-10-09	G.D. Searle & Co.	Derives de phenylene meta-substitues, utilises comme antagonistes ou inhibiteurs de l'integrine alphavbeta3
DE69710319T2 (de) *	1996-03-29	2002-08-14	G.D. SEARLE & CO., CHICAGO	Para-substituierte phenylpropansäure derivate als integrin-antagonisten
SK5462000A3 (en) *	1997-10-31	2001-02-12	Aventis Pharma Ltd	Substituted anilides

1998
- 1998-12-23 JP JP2000526473A patent/JP4555469B2/ja not_active Expired - Lifetime
- 1998-12-23 CA CA002316235A patent/CA2316235A1/fr not_active Abandoned
- 1998-12-23 EP EP98962586A patent/EP1042279B1/fr not_active Expired - Lifetime
- 1998-12-23 ES ES98962586T patent/ES2235383T3/es not_active Expired - Lifetime
- 1998-12-23 CN CNB988125005A patent/CN1163477C/zh not_active Expired - Fee Related
- 1998-12-23 TR TR2000/01947T patent/TR200001947T2/xx unknown
- 1998-12-23 IL IL13658498A patent/IL136584A/xx not_active IP Right Cessation
- 1998-12-23 AT AT98962586T patent/ATE289991T1/de not_active IP Right Cessation
- 1998-12-23 HU HU0101701A patent/HUP0101701A3/hu unknown
- 1998-12-23 KR KR1020007007022A patent/KR20010033520A/ko not_active Ceased
- 1998-12-23 WO PCT/GB1998/003859 patent/WO1999033789A1/fr not_active Ceased
- 1998-12-23 CZ CZ20002342A patent/CZ20002342A3/cs unknown
- 1998-12-23 BR BR9814376-0A patent/BR9814376A/pt not_active Application Discontinuation
- 1998-12-23 AU AU17719/99A patent/AU747907B2/en not_active Ceased
- 1998-12-23 DE DE69829215T patent/DE69829215T2/de not_active Expired - Lifetime
- 1998-12-23 SK SK937-2000A patent/SK9372000A3/sk unknown
- 1998-12-23 NZ NZ505363A patent/NZ505363A/en unknown
2000
- 2000-06-22 NO NO20003273A patent/NO20003273D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL136584A (en)	2005-03-20
EP1042279B1 (fr)	2005-03-02
NZ505363A (en)	2005-02-25
EP1042279A1 (fr)	2000-10-11
CZ20002342A3 (cs)	2001-11-14
WO1999033789A1 (fr)	1999-07-08
CN1163477C (zh)	2004-08-25
HUP0101701A2 (hu)	2001-11-28
JP4555469B2 (ja)	2010-09-29
ES2235383T3 (es)	2005-07-01
NO20003273L (no)	2000-06-22
KR20010033520A (ko)	2001-04-25
JP2001527061A (ja)	2001-12-25
TR200001947T2 (tr)	2001-01-22
AU1771999A (en)	1999-07-19
BR9814376A (pt)	2000-10-10
DE69829215D1 (de)	2005-04-07
HUP0101701A3 (en)	2003-02-28
DE69829215T2 (de)	2005-07-21
CA2316235A1 (fr)	1999-07-08
ATE289991T1 (de)	2005-03-15
AU747907B2 (en)	2002-05-30
NO20003273D0 (no)	2000-06-22
HK1034508A1 (en)	2001-10-26
CN1283181A (zh)	2001-02-07
IL136584A0 (en)	2001-06-14

Publication	Publication Date	Title
SK9372000A3 (en)	2002-03-05	Substituted beta-alanines
EP1114028B1 (fr)	2006-11-29	Bicycles aza modulant l'inhibition de l'adhesion cellulaire
EP1027328B1 (fr)	2006-08-23	Anilides substituees
EP1183254B1 (fr)	2005-01-12	Composes d'heteroaryle bicyclique substitue utilises comme antagonistes de l'integrine
EP1153017B1 (fr)	2006-05-03	Composes bicycliques et leur utilisation comme ligands du recepteur de l'integrine
JP2001523711A (ja)	2001-11-27	細胞接着阻害薬としての環状アミノ酸誘導体
EP1392306B1 (fr)	2008-01-16	Tetrahydroisoquinolines substituees destinees au traitement des maladies inflammatoires
EP1177181B1 (fr)	2009-01-28	Composes bicycliques substitues
WO1999054321A1 (fr)	1999-10-28	Diamines substituees et leur utilisation en tant qu'inhibiteurs d'adhesion cellulaire
US6352977B1 (en)	2002-03-05	Substituted β-alanines
US20040006056A1 (en)	2004-01-08	Substituted alkanoic acids
US6762199B2 (en)	2004-07-13	Indane derivatives
US6548533B2 (en)	2003-04-15	Ureido substituted pyrrolidines
ES2297943T3 (es)	2008-05-01	Dihidro-benzo(1,4)oxacinas y tetrahidroquinoxalinas.
MXPA00006218A (en)	2002-02-26	SUBSTITUTED&bgr;-ALANINES
JP4856314B2 (ja)	2012-01-18	置換ピロリジン